Cargando…

Novel immune modulatory vaccines targeting TGFβ

Detalles Bibliográficos
Autor principal:	Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040921/ https://www.ncbi.nlm.nih.gov/pubmed/36973484 http://dx.doi.org/10.1038/s41423-023-01000-5

Ejemplares similares

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
por: Perez-Penco, Maria, et al.
Publicado: (2022)

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020)

The immune-modulatory effects of exercise should be favorably harnessed against COVID-19
por: Codella, R., et al.
Publicado: (2020)

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2021)

The targeting of tumor-associated macrophages by vaccination
por: Andersen, Mads Hald
Publicado: (2019)

TGF-β Inhibitor CILP as a Novel Biomarker for Cardiac Fibrosis
por: Groß, Sonja, et al.
Publicado: (2020)

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
por: Andersen, Mads Hald
Publicado: (2012)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

FOXP3-specific immunity
por: Andersen, Mads Hald
Publicado: (2013)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Vaccine efficacy and immune interference: co-administering COVID-19 and influenza vaccines
por: Altmann, Daniel M, et al.
Publicado: (2022)

The elusive goal of COVID-19 vaccine immunity
por: Abu-Raddad, Laith J, et al.
Publicado: (2023)

Hybrid immunity and strategies for COVID-19 vaccination
por: Hui, David S
Publicado: (2023)

Population immunity and vaccine protection against infection
por: Leshem, Eyal, et al.
Publicado: (2021)

Vaccine safety in an era of novel vaccines: a proposed research agenda
por: Poland, Gregory A., et al.
Publicado: (2022)

Herd immunity or health equity? – extending HPV vaccination
por: Keddy, Karen H., et al.
Publicado: (2023)

Lessons from vaccine-induced immune thrombotic thrombocytopenia
por: Kelton, John Greenhow, et al.
Publicado: (2021)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination
por: Irving, Stephanie A, et al.
Publicado: (2023)

COVID-19 vaccine design: the Janus face of immune enhancement
por: Hotez, Peter J., et al.
Publicado: (2020)

COVID-19 vaccines: modes of immune activation and future challenges
por: Teijaro, John R., et al.
Publicado: (2021)

Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis
por: Boekel, Laura
Publicado: (2022)

COVID-19 vaccination in patients with immunity-mediated kidney disease
por: Prendecki, Maria, et al.
Publicado: (2021)

Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases
por: Sparks, Jeffrey A, et al.
Publicado: (2022)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

A Potential Role of Indoleamine 2,3-Dioxygenase–Specific T cells in Leishmania Vaccination
por: Straten, Per thor, et al.
Publicado: (2011)

Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases
por: Shenoy, Padmanabha, et al.
Publicado: (2022)

Evaluating novel COVID-19 vaccines in the current chapter of the pandemic
por: GeurtsvanKessel, Corine H, et al.
Publicado: (2022)

COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges
por: Phelan, Alexandra L
Publicado: (2020)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Vaccination and natural immunity: Advantages and risks as a matter of public health policy
por: Biggs, Adam T., et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
por: Anderson, Roy M, et al.
Publicado: (2020)

Liver targeting with rAAV7: balancing tropism with immune profiles
por: Flotte, Terence R.
Publicado: (2021)

Emerging mechanisms and novel targets in allergic inflammation and asthma
por: Weiss, Scott T.
Publicado: (2017)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Exploring BCG vaccination as a novel approach to prevent recurrent herpes labialis
por: Gong, Wenping, et al.
Publicado: (2023)

Novel insights into the role of anti-inflammatory IL-38 in immunity against infection
por: Gao, Xun, et al.
Publicado: (2022)

Natural immunity helps overcome the age-related decline of SARS-CoV-2 vaccine immunogenicity
por: Verschoor, Chris P, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v736q5cpk0dii5bknmka91o0j2